

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7840497

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CURTIS COLWELL	11/14/2022
SAMIR BOUAYAD-GERVAIS	11/14/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PARAZA PHARMA, INC.
<b>Street Address:</b>	2525 MARIE-CURIE AVENUE
<b>City:</b>	MONTREAL
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	H4S 2E1
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	63344025
<b>Application Number:</b>	18057738
<b>PCT Number:</b>	US2022080281
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6502557894
<b>Email:</b>	guittap.mark@gene.com
<b>Correspondent Name:</b>	MARK GUITTAP
<b>Address Line 1:</b>	1 DNA WAY
<b>Address Line 2:</b>	MAIL STOP 49
<b>Address Line 4:</b>	SOUTH SAN FRANCISCO, CALIFORNIA 94080
<b>ATTORNEY DOCKET NUMBER:</b>	P37243-US-1, -US-3, -WO
<b>NAME OF SUBMITTER:</b>	MARK GUITTAP
<b>SIGNATURE:</b>	/Mark Guittap/
<b>DATE SIGNED:</b>	03/10/2023
<b>Total Attachments: 5</b>	
source=6-P37243-US-1 Signed (not recorded) Paraza Inv to Paraza Confirmatory Assignment#page1.tif	
source=6-P37243-US-1 Signed (not recorded) Paraza Inv to Paraza Confirmatory Assignment#page2.tif	

source=6-P37243-US-1 Signed (not recorded) Paraza Inv to Paraza Confirmatory Assignment#page3.tif  
source=6-P37243-US-1 Signed (not recorded) Paraza Inv to Paraza Confirmatory Assignment#page4.tif  
source=6-P37243-US-1 Signed (not recorded) Paraza Inv to Paraza Confirmatory Assignment#page5.tif

## CONFIRMATORY ASSIGNMENT

WHEREAS, **Curtis COLWELL**, and **Samir BOUAYAD-GERVAIS** ("ASSIGNORS"), have invented new and useful invention(s) as set forth in the application(s) listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A**; and

WHEREAS, Paraza Pharma, Inc., a corporation having a place of business at 2525 Marie-Curie Avenue, Montreal, Quebec H4S 2E1, Canada, ("PARAZA"), is desirous of confirming its ownership interest in and to the **INVENTION** and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR(S) confirm that, by virtue of their employment agreement with PARAZA, prior to, and no later than the earliest filing date of the application(s) listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR(S) had assigned to PARAZA, any and all of their right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the **INVENTION**, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNOR(S) agree and authorize PARAZA, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by PARAZA, its successors, assigns and delegates in and to the **INVENTION** when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR(S). ASSIGNOR(S) agree and acknowledge that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of PARAZA, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR(S), their respective heirs, successors and assigns.

IN WITNESS WHEREOF the ASSIGNOR(S) and PARAZA have executed this Confirmatory Assignment and accepted the terms thereof.

Curtis Colwell November 14<sup>th</sup>, 2022  
Curtis COLWELL Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: CA

Jana Paraz  
Witness (signature)

Samir Bouayad-Gervais Nov. 14<sup>th</sup>, 2022  
Samir BOUAYAD-GERVAIS Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: CA

Jana Paraz  
Witness (signature)

M. A. Siddiqui 11/17/2022  
Paraza Pharma, Inc. Date

Name: AKSHAD SIDDIQUI  
Title: PRESIDENT + CEO

**EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
<b>P37243-US-1</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE</b>	<b>63/344025</b>	<b>19 May 2022</b>

\*As agreed in this Confirmatory Assignment, ASSIGNOR(S) hereby authorize PARAZA, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by PARAZA, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR(S).

**UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>

**UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
<b>P37243-US-1</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE</b>	<b>63/344025</b>	<b>May 19, 2022</b>
<b>P37243-US-3</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE</b>	<b>18/057738</b>	<b>November 21, 2022</b>
<b>P37243-WO</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE</b>	<b>PCT/US2022/080281</b>	<b>November 21, 2022</b>
<b>P37243-AR</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE</b>	<b>P220103201</b>	<b>November 22, 2022</b>
<b>P37243-TW</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE</b>	<b>111144474</b>	<b>November 21, 2022</b>